Indian pharma major Lupin Limited, on Tuesday (21) spun off two oncology programmes, LNP7457 (PRMT5) and LNP8701 (SOS1), to Kaveri Therapeutics Inc, a US-based clinical-stage oncology company.
Under the terms of the agreement, the Mumbai-headquartered company, through its wholly owned subsidiary - Lupin Inc, will have a significant equity stake in Kaveri, provide seed funding, and grant them exclusive rights to the programmes.
Kaveri will raise additional capital to fund its clinical development efforts and operate as an independent entity.
Both programmes have demonstrated encouraging clinical progress, with LNP7457 (PRMT5) and LNP8701 (SOS1) each reporting positive data at the American Society of Clinical Oncology (ASCO) meeting in 2025 and 2026, respectively.
Kaveri will be led by Chief Executive Officer Kristi Jones and Chief Medical Officer Dr Robert Pierce, both having expertise in their respective fields.
“We are proud to have pioneered these oncology assets and look forward to advancing them through Kaveri Therapeutics,” said Vinita Gupta, Chief Executive Officer, Lupin.
“The strength of these assets, combined with Kaveri’s seasoned leadership team, positions us to accelerate the development of targeted oncology therapies with the goal of bringing meaningful innovation to patients,” she added.
